Danmar Domingo
Adult Health · Ann Arbor, MINPI 1104384106
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 307 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,210 and has fallen 99.2% since, to $17 in 2024. Among adult health clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 307 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$984
- Lilly USA, LLC$511
- Amgen$339
- Amarin Pharma, Inc.$337
- Sanofi-aventis U.S. LLC$268
- Xeris Pharmaceuticals, Inc.$236
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,907100%
- Education$240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 81 | $984 |
| Lilly USA, LLC | 28 | $511 |
| Amgen(2 entities) | 22 | $339 |
| Amarin Pharma, Inc. | 19 | $337 |
| Sanofi-aventis U.S. LLC | 15 | $268 |
| Xeris Pharmaceuticals, Inc. | 14 | $236 |
| Dexcom, Inc. | 11 | $211 |
| AbbVie | 11 | $211 |
| AstraZeneca(2 entities) | 11 | $184 |
| Amneal Pharmaceuticals LLC | 9 | $183 |
| Antares Pharma, Inc. | 11 | $177 |
| BD | 9 | $135 |
| Abbott | 6 | $131 |
| Corcept Therapeutics | 6 | $113 |
| Boehringer Ingelheim | 6 | $102 |
| Mannkind Corporation | 6 | $89 |
| Merck | 6 | $83 |
| Bayer | 4 | $76 |
| Recordati_rare_diseases_inc. | 4 | $75 |
| Alvogen Inc | 4 | $68 |
| Amryt Pharma Holdings Ltd | 4 | $55 |
| Ascendis Pharma Endocrinology Inc | 2 | $46 |
| IBSA Pharma Inc. | 3 | $42 |
| Zealand Pharma US, Inc. | 2 | $37 |
| Embecta Corp. | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Currax Pharmaceuticals LLC | 2 | $28 |
| Lifescan, Inc. | 2 | $25 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| EUSA Pharma (US) LLC | 1 | $22 |
| Nevro Corp. | 1 | $22 |
| Radius Health, Inc. | 1 | $18 |
| Medtronic | 1 | $17 |
| Alfasigma USA, Inc. | 1 | $16 |
How this compares
$4,931 in reported general payments places this provider in the 90th percentile of 527 adult health providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 111 | $194,238 |
| MounjaroTirzepatide | 61 | $92,057 |
| JardianceEmpagliflozin | 63 | $82,712 |
| TrulicityDulaglutide | 37 | $56,972 |
| FarxigaDapagliflozin Propanediol | 33 | $38,560 |
| Novolog FlexpenInsulin Aspart | 55 | $22,086 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 49 | $21,653 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 129 | $19,814 |
| Gvoke Hypopen 1-PackGlucagon | 22 | $18,869 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $15,294 |
| Humalog Kwikpen U-100Insulin Lispro | 36 | $13,232 |
| Gvoke Hypopen 2-PackGlucagon | 17 | $11,099 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 41 | $5,316 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 30 | $4,046 |
| SynthroidLevothyroxine Sodium | 30 | $3,366 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $984 | $194,238111 claims |
| Lilly USA, LLCMounjaro, Trulicity | $511 | $149,03098 claims |
| Boehringer IngelheimJardiance | $102 | $82,71263 claims |
| AstraZenecaFarxiga | $184 | $38,56033 claims |
| AbbVieSynthroid | $211 | $3,36630 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $183 | $1,46198 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 527 adult health providers in Michigan.
Other adult health in Ann Arbor
- Susanne QuallichAnn Arbor$42K
- Deniene KingAnn Arbor$14K
- Wei LuoAnn Arbor$4K
- Jacqueline BrewerSterling Heights$138K
- Linda Morris McCoyGrand Rapids$59K
- Sarita RaoCanton$51K
- Nancy BermanSouthfield$39K
- Michelle MillerQuincy$24K
- Adama JohnsonEastpointe$14K
- Bridget BonelloWyandotte$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.